Name Mark W. Burket
Country United States
Job Interventional Cardiologist

Other content(s) by This Presenter

  1. Zilver PTX Randomized Trial of Paclitaxel-Eluting Stents for Femoropopliteal Artery Disease: 24-Month Update
  2. Evolving Horizon: Drug-coated Balloons or Drug-coated Stents in SFA Diseases?
  3. Will Drug-coated Balloons, Drug-coated Stents Shift the Paradigm for Femoropopliteal Lesion
  4. The Drug Eluting Stent in the SFA
  5. Where Are We Now? Current Scientific Evidences from Clinical Trials and Upcoming New Horizon
  6. DES vs. DCB: When to Choose?
  7. Drug-eluting Balloon or Stent in Femoropopliteal Lesions: How Far We Are ?
  8. Drug Eluting Stent Will Be Most Promising in Lower Limb Arterial Disease
  9. Zilver PTX 2 Year Data
  10. DES in Lower Extremity Intervention: Changed Landscape in the Current Practice ?
  11. [Great Debate] Con: There Always Be a Need for Stenting for Femoropopliteal Lesion
  12. Proximal Protection Grabs the Initiative
  13. Strong Supporter for Lumen Patency: Clear Long-term Efficacy of DES
  14. Customization of Carotid Revascularization Management to Optimize Outcomes
  15. Percutaneous Reconstruction of Complex Aorto-Iliac Disease: Tips from Imaging to Intervention
  16. Zilver PTX 5-year Data: What Does It Mean to Clinical Practice?
  17. Does Carotid Stent Cell Design Matter?: Open vs. Closed vs. Micromesh
  18. Drug-Eluting Stents in the SFA(Zilver PTX or ELUVIA): Why Not Now? What Needed for the Future?
  19. Current and Upcoming Evidence-Based Approach in CLI: Endovascular vs. Surgery (OLIVE 3-Year and BEST-CLI Trial)
  20. Next-Generation DCBs: "Make It Different?"
  21. Cost Effectiveness of Endovascular Procedures - Can We Afford These Expensive Technologies?
  22. The Modern Endovascular Approach to Infrapopliteal Occlusive Disease
  23. Prognosis of the CLI patient - From Olive to Wifi